EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Combining Immune Checkpoint Inhibitors with Loco-Regional Treatments in Hepatocellular Carcinoma: Ready for Prime Time?

Juliette Boilève, Valentine Guimas iD, Arthur David, Clément Bailly iD, Yann Touchefeu

Current Oncology · 2024

DOI: 10.3390/curroncol31060242 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, 2024. Verfasst von Juliette Boilève und 4 weiteren Autor:innen. Beteiligte Einrichtung: Inserm CIC 1413, Hépato-Gastroentérologie, Institut des Maladies de l'Appareil Digestif (IMAD), CHU Nantes, Nantes Université, 44000 Nantes, France. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is a disease with a poor prognosis, often diagnosed at an advanced stage. Therapeutic options have developed considerably in recent years, particularly with trans-arterial treatments. Systemic treatments have also evolved significantly, with the rise of immune checkpoint inhibitors (ICI) as first-line treatment for advanced HCC. The combination of loco-regional treatments and ICI is opening up new prospects and is the subject of numerous clinical trials. Recently, two global phase 3 trials investigating ICI-based adjuvant combinations have demonstrated improvements in recurrence-free survival or progression-free survival in patients treated with resection, ablation, or trans-arterial chemoembolization. However, mature data and overall survival results are still awaited but will be difficult to interpret. We are at the start of a new era of combinations of loco-regional treatments and immunotherapy. The identification of the best therapeutic strategies and predictive biomarkers is a crucial issue for future standards in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsImmune Checkpoint InhibitorsHumansCombined Modality TherapyImmunotherapyChemoembolization, Therapeutic

Stichwörter der Autor:innen

adjuvant therapyhepatocellular carcinomaimmune checkpoint inhibitorslocoregional treatmentradio-frequency ablationselective internal radiation therapytrans-arterial chemoembolization

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Inserm CIC 1413, Hépato-Gastroentérologie, Institut des Maladies de l'Appareil Digestif (IMAD), CHU Nantes, Nantes Université, 44000 Nantes, France.
  • Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Bd Professeur Jacques Monod, 44800 Saint-Herblain, France.
  • Department of Radiology, University Hospital, Nantes 1 Place Alexis Ricordeau, 44093 Nantes, France.
  • Nuclear Medicine Department, University Hospital, 44093 Nantes, France.

ORCID-Profile: Valentine Guimas, Clément Bailly

Zitieren

APA

Boilève, J., Guimas, V., David, A., Bailly, C., & Touchefeu, Y. (2024). Combining Immune Checkpoint Inhibitors with Loco-Regional Treatments in Hepatocellular Carcinoma: Ready for Prime Time?. Current Oncology. https://doi.org/10.3390/curroncol31060242

Vancouver

Boilève J, Guimas V, David A, Bailly C, Touchefeu Y. Combining Immune Checkpoint Inhibitors with Loco-Regional Treatments in Hepatocellular Carcinoma: Ready for Prime Time?. Current Oncology. 2024. doi:10.3390/curroncol31060242

BibTeX
@article{Boilve2024,
  author = {Boilève, Juliette and Guimas, Valentine and David, Arthur and Bailly, Clément and Touchefeu, Yann},
  title = {Combining Immune Checkpoint Inhibitors with Loco-Regional Treatments in Hepatocellular Carcinoma: Ready for Prime Time?},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol31060242}
}
Kostenlos starten →